Yantai Key Laboratory of Pharmacology of Traditional Chinese Medicine in Tumor Metabolism, School of Integrated Traditional Chinese and Western Medicine, Binzhou Medical University, 264003, Yantai, China.
Department of Pharmacy, Yantai Yuhuangding Hospital Affiliated to Qingdao University, 264000, Yantai, China.
Recent Pat Anticancer Drug Discov. 2019;14(2):187-197. doi: 10.2174/1574891X14666190516102218.
A recent patent has been issued for hydroxysafflor yellow A (HSYA) as a drug to prevent blood circulation disorders. Hydroxysafflor yellow B (HSYB), an isomer of HSYA with antioxidative effects, has been isolated from the florets of Carthamus tinctorius. The effects of HSYB on the proliferation of cancer cells and its mechanism of action have not been investigated.
The aims of this study were to investigate the anti-cancer effects and the molecular mechanism of HSYB for breast cancer MCF-7 cells.
MTT assays and colony formation assays were used to assess the survival and proliferation of MCF-7 cells, respectively. Hoechst 33258 and flow cytometry were used to measure cell apoptosis and flow cytometry to determine effects on the cell cycle. Western blots were used to measure protein levels.
Treatment with HSYB reduced survival and proliferation of human breast cancer MCF-7 cells in a dose-dependent manner. Furthermore, HSYB arrested the MCF-7 cell cycle at the S phase and downregulated cyclin D1, cyclin E, and CDK2. Compared with a control group, HSYB suppressed the protein levels of p-PI3K, PI3K, AKT, and p-AKT in MCF-7 cells. In addition, HSYB decreased the levels of Bcl- 2, increased the levels of Bax, cleaved caspase-3 and caspase-9, and subsequently induced MCF-7 cell apoptosis.
These data demonstrate that HSYB arrests the MCF-7 cell cycle at the S phase and induces cell apoptosis. Patent US20170246228 indicates that HSYB can be potentially used for the prevention and treatment of human breast cancer.
最近有一项专利针对羟基红花黄色素 A（HSYA）作为预防血液循环障碍的药物。羟基红花黄色素 B（HSYB）是 HSYA 的异构体，具有抗氧化作用，已从红花的花中分离出来。HSYB 对癌细胞增殖的影响及其作用机制尚未得到研究。
本研究旨在探讨 HSYB 对乳腺癌 MCF-7 细胞的抗癌作用及其作用机制。
采用 MTT 法和集落形成实验分别检测 MCF-7 细胞的存活和增殖情况。Hoechst 33258 和流式细胞术用于检测细胞凋亡，流式细胞术用于检测细胞周期。Western blot 用于检测蛋白水平。
HSYB 以剂量依赖性方式降低人乳腺癌 MCF-7 细胞的存活率和增殖能力。此外，HSYB 将 MCF-7 细胞周期阻滞在 S 期，并下调 cyclin D1、cyclin E 和 CDK2。与对照组相比，HSYB 抑制 MCF-7 细胞中 p-PI3K、PI3K、AKT 和 p-AKT 的蛋白水平。此外，HSYB 降低了 Bcl-2 的水平，增加了 Bax、cleaved caspase-3 和 caspase-9 的水平，随后诱导 MCF-7 细胞凋亡。
这些数据表明，HSYB 将 MCF-7 细胞周期阻滞在 S 期并诱导细胞凋亡。专利 US20170246228 表明，HSYB 可潜在用于预防和治疗人类乳腺癌。
